Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
- Navigating Outsourced Pharmaceutical Testing Through Today's Geopolitical Uncertainty
- Is Your Supply Chain Ready For The End Of Class VI?
- On The Ground At BPI: Tatyana Matveeva, Ph.D., On Distributed Manufacturing Models
- When Lyophilization Fails At Scale, First Scrutinize Your Formulation
- Contextualizing Data To Enable AI And Prevent Knowledge Leaks
- The 5 Shifts That Could Remake Lyophilization By 2040
- On The Ground At BPI: Jacqualyn Schulman, Ph.D., On Accelerating Clonal CLD
EDITOR'S DESK
-
On The Ground At BPI: Jacqualyn Schulman, Ph.D., On Accelerating Clonal CLD
An interview with Jacqualyn Schulman, Ph.D., a principal scientist at Bristol Myers Squibb (BMS), on her presentation at BPI 2026, “Fast-Tracking CHO Cell Line Development Using Integrated Engineering Strategies.”
This article captures key takeaways from a BioProcess International keynote by Preeya Boppana, director of MSAT process analytics and laboratories at AstraZeneca, titled “Transforming Biologics Manufacturing: Leveraging Predictive Analytics and Advanced Process Control for Next-Generation Operations.”
Regulatory compliance and cGMP manufacturing expert Tatyana Matveeva, Ph.D., explains the role and importance of a quality unit in an organization, as well as what happens when it’s compromised.
Experts discuss where productivity gains can be achieved and how development teams should seek to improve process performance in this recap of the Bioprocess Online Live event "The Levers And Tradeoffs That Drive Process Productivity."
Siren Biotechnology's SVP of vector development, Nathalie Clément, Ph.D., explains the challenge of purifying AAV capsids and the ways developers are optimizing vector recovery.
GUEST COLUMNISTS
-
Is Your Supply Chain Ready For The End Of Class VI?
Revisions to USP <87> and <88> update biological reactivity testing — changes that are especially important for companies that rely on single-use technology.
-
When Lyophilization Fails At Scale, First Scrutinize Your Formulation
When lyophilizing a challenging biologic drug product, use an integrated approach optimizing formulation and process parameters together.
-
The 5 Shifts That Could Remake Lyophilization By 2040
Purdue University-based LyoHUB charts a risk-based course to modernizing freeze-drying technology for better performance and advanced modalities.
-
Complete Response Letters For CGTs Share This Common Theme
One expert’s analysis found CMC-related concerns in about 75% of complete response letters. He outlines a path to stronger CMC readiness for cell and gene therapies.
-
Your 7 Decisions To Make Before MES Configuration
Don't wait until manufacturing execution system (MES) configuration to answer these 7 questions. Define your manufacturing process before digitizing it.
-
DEA Reveals Hidden Costs Of Analytical Validation Guidelines
By treating distinct validation guidelines as decision-making units, data envelopment analysis (DEA) allows for the mathematical evaluation of their resource efficiency.
-
Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
Systemic vulnerabilities exist in thermal uniformity assurance, steam penetration verification, regulatory fragmentation, and tech harmonization.
-
FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
The proposed revision reflects changes in packaging technology, drug delivery systems, quality risk management, and more that have occurred since 1999's guidance.
BIOPROCESSING WHITE PAPERS
-
Modular Automation: The Plug-And-Produce Opportunity For Life Sciences
Explore how the advantages of modular automation in life sciences emphasize flexibility, efficiency, and cost savings through plug-and-produce systems that enhance production adaptability and speed.
-
Comparing In-Line Vs At-Line Variable Pathlength Tech For UF/DF11/20/2025
Discover how rapid amino acid profiling improves media insight, detects variability, and supports real-time optimization for stronger bioprocess control, as well as strategies to reduce risk.
-
Random And Semi-Targeted Integration In Cell Line Development8/5/2025
While semi-targeted approaches may offer precision, uncover how they may fall short in overall efficiency and productivity, especially in late-stage manufacturing.
-
Data-Centric Organoid Services For Predictive Drug Response And Next-Generation Oncology Research10/1/2026
Patient-derived organoids are gaining traction as translational tools in oncology, but their value depends on the quality and context of the data they generate, not the models alone.
-
Exploring The Future Of Cell Expansion In Cell Therapy Manufacturing6/26/2026
As cell therapy scales, success depends on more than clinical promise. Smarter expansion strategies, automation, and flexible manufacturing platforms are becoming critical for improving consistency.
-
The Essential Ingredient For GxP Training Innovation6/4/2026
Advanced learning tools depend entirely on the health of the underlying training matrix. Establish a clean, data-driven framework to reduce compliance risks and recover lost operational hours.
BIOPROCESSING APP NOTES & CASE STUDIES
- On The Ground At BPI: Where AI Dreams Meet Operational Reality
- On The Ground At BPI: Tatyana Matveeva, Ph.D., On Distributed Manufacturing Models
- Contextualizing Data To Enable AI And Prevent Knowledge Leaks
- On The Ground At BPI: Jacqualyn Schulman, Ph.D., On Accelerating Clonal CLD
- AstraZeneca's Focus On Predictive Control, Semi-Autonomous Processing
- Prioritizing Quality Over Everything
- Evaluating The Levers Driving Productivity In Bioprocessing
EDITORIAL COLLECTIONS KNOWLEDGE CENTER
Editorial Collections are subscriber-only, curated resources that combine expert interviews, feature articles, and industry analysis to help readers better understand emerging trends, operational challenges, regulatory developments, and best practices shaping the biopharma industry.
More Editorial CollectionsFEATURED PRODUCTS AND SERVICES
ON-DEMAND WEBINARS
- Unlocking Hidden Efficiencies In Cell And Gene Therapy Manufacturing
- Connecting Oligonucleotide R&D With Early Clinical Scale Manufacturing
- Bioconjugation Scale-Up: Data-Driven Strategies From 10 L To 500 L
- Maximize Exosome Yields Using a Chemically Defined Bioreactor Media System
- Maintaining Process Consistency And Performance During Scale-Up
INDUSTRY NEWS
NEWSLETTER ARCHIVE
- 10.29.26 -- Fluid Management Solutions To Strengthen Yield, Control, And Efficiency
- 10.28.26 -- Beyond Speed & Titer: Building Cell Lines That Scale
- 10.28.26 -- Building More Scalable MSC Processes
- 10.28.26 -- When Lyophilization Fails At Scale, First Scrutinize Your Formulation
- 10.27.26 -- Accelerating Advanced Therapies: From Development To Manufacturing

